Although steroids are the most widely used treatment for sudden hearing loss, little scientific evidence supports their use or that of any other therapies for this condition, according to a systematic review and meta-analysis both published in the June issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology, one of the JAMA/Archives journals.
The U.S. Food and Drug Administration (FDA) approved Letairis (ambrisentan) for the treatment of pulmonary arterial hypertension, a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the lungs.
Weight loss OTC diet pill Alli works with regular physical activity, exercise and good food with low calorie diet. The first and only over-the-counter product for weight loss approved by the Food and Drug Administration is available in US now.
Deguelin, a natural compound known to have antitumor properties, appears to disrupt the function of heat shock protein 90 (Hsp90), which cancer cells may need to grow.
Results of the Option (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial, the first multinational Phase III study outside of Japan, showed that patients treated with Actemra (either 4mg/kg or 8mg/kg) plus methotrexate achieved a significant and clinically important improvement in the signs and symptoms of moderate to severe rheumatoid arthritis (RA) compared to patients treated with placebo and methotrexate, a current standard of care.
Two studies presented today demonstrated that ROZEREM did not affect body sway at peak plasma levels, nor did it impair middle-of-the-night balance, mobility or memory performance in patients who suffer from chronic insomnia. The results of the studies were presented at the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).
Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a European study presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Treatment with denosumab 60 mg and 180 mg, with background methotrexate, reduces the progression of bone erosion according to results of a 227 patient-Phase II trial presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Data presented today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE? (infliximab) over two years experienced significant improvement in spinal mobility.